Targeting these newly identified AR-circHIAT1- miR-195-5p/29a-3p/29c-3p/CDC42 and ERβ-circATP2B1-mediated miR-204-3p/FN1 signaling cascades can be a potential new route for development of therapies for metastatic ccRCC [49, 50]. The gene discussed is ESR2; the disease is nonpapillary renal cell carcinoma.